Literature DB >> 10191337

Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.

R J Carter1, L A Lione, T Humby, L Mangiarini, A Mahal, G P Bates, S B Dunnett, A J Morton.   

Abstract

Transgenic mice expressing exon 1 of the human Huntington's disease (HD) gene carrying a 141-157 CAG repeat (line R6/2) develop a progressive neurological phenotype with motor symptoms resembling those seen in HD. We have characterized the motor deficits in R6/2 mice using a battery of behavioral tests selected to measure motor aspects of swimming, fore- and hindlimb coordination, balance, and sensorimotor gating [swimming tank, rotarod, raised beam, fore- and hindpaw footprinting, and acoustic startle/prepulse inhibition (PPI)]. Behavioral testing was performed on female hemizygotic R6/2 transgenic mice (n = 9) and female wild-type littermates (n = 22) between 5 and 14 weeks of age. Transgenic mice did not show an overt behavioral phenotype until around 8 weeks of age. However, as early as 5-6 weeks of age they had significant difficulty swimming, traversing the narrowest square (5 mm) raised beam, and maintaining balance on the rotarod at rotation speeds of 33-44 rpm. Furthermore, they showed significant impairment in prepulse inhibition (an impairment also seen in patients with HD). Between 8 and 15 weeks, R6/2 transgenic mice showed a progressive deterioration in performance on all of the motor tests. Thus R6/2 mice show measurable deficits in motor behavior that begin subtly and increase progressively until death. Our data support the use of R6/2 mice as a model of HD and indicate that they may be useful for evaluating therapeutic strategies for HD, particularly those aimed at reducing the severity of motor symptoms or slowing the course of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10191337      PMCID: PMC6782264     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  19 in total

1.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.

Authors:  M F Beal; N W Kowall; D W Ellison; M F Mazurek; K J Swartz; J B Martin
Journal:  Nature       Date:  1986 May 8-14       Impact factor: 49.962

2.  Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.

Authors:  M C Guyot; P Hantraye; R Dolan; S Palfi; M Maziére; E Brouillet
Journal:  Neuroscience       Date:  1997-07       Impact factor: 3.590

3.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

4.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

Review 5.  Huntington's disease: translating a CAG repeat into a pathogenic mechanism.

Authors:  M E MacDonald; J F Gusella
Journal:  Curr Opin Neurobiol       Date:  1996-10       Impact factor: 6.627

6.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.

Authors:  M F Beal; E Brouillet; B G Jenkins; R J Ferrante; N W Kowall; J M Miller; E Storey; R Srivastava; B R Rosen; B T Hyman
Journal:  J Neurosci       Date:  1993-10       Impact factor: 6.167

7.  Striatal transplantation in a transgenic mouse model of Huntington's disease.

Authors:  S B Dunnett; R J Carter; C Watts; E M Torres; A Mahal; L Mangiarini; G Bates; A J Morton
Journal:  Exp Neurol       Date:  1998-11       Impact factor: 5.330

8.  Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.

Authors:  C V Borlongan; T K Koutouzis; T B Freeman; D W Cahill; P R Sanberg
Journal:  Brain Res       Date:  1995-10-30       Impact factor: 3.252

9.  The quinolinic acid model of Huntington's disease: locomotor abnormalities.

Authors:  P R Sanberg; S F Calderon; M Giordano; J M Tew; A B Norman
Journal:  Exp Neurol       Date:  1989-07       Impact factor: 5.330

10.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.

Authors:  E Brouillet; P Hantraye; R J Ferrante; R Dolan; A Leroy-Willig; N W Kowall; M F Beal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

View more
  330 in total

1.  Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Authors:  A S Harris; E M Denovan-Wright; L C Hamilton; H A Robertson
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

2.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice.

Authors:  J A Bibb; Z Yan; P Svenningsson; G L Snyder; V A Pieribone; A Horiuchi; A C Nairn; A Messer; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 3.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

4.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

5.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

6.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

7.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

8.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning.

Authors:  Laura Formentini; Marta P Pereira; Laura Sánchez-Cenizo; Fulvio Santacatterina; José J Lucas; Carmen Navarro; Alberto Martínez-Serrano; José M Cuezva
Journal:  EMBO J       Date:  2014-02-12       Impact factor: 11.598

10.  Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.

Authors:  Hong Zheng; Wen-Mei Yu; Ronald R Waclaw; Maria I Kontaridis; Benjamin G Neel; Cheng-Kui Qu
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.